CLINICAL TRIALS PROFILE FOR CHLORPROTHIXENE

All Clinical Trials for CHLORPROTHIXENE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01309178 ↗	Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo	Unknown status	Universität Duisburg-Essen	Phase 2	2009-05-01	Cystic fibrosis patients suffer from a chronic destruction of the lung, frequent and finally chronic pneumonia and a reduced life expectancy. Unfortunately, no curative treatment for cystic fibrosis is available, neither are treatments established that prevent the disease. Our data identify ceramide as a potential novel target to treat cystic fibrosis. Two smaller trials support the notion that inhibition of the acid sphingomyelinase by amitriptyline improves the lung function of CF-patients even at a dose that is low enough to avoid adverse effects. In the present proposal the investigators, therefore, aim to test in a larger cystic fibrosis patient population whether an inhibition of ceramide release in the lung caused by the lack of functional CFTR improves the lung function of cystic fibrosis patients. Inhibition of ceramide-release in the lung will be achieved by treatment with amitriptyline, which is used as an anti-depressant drug for almost 50 years. Although it is not absolutely specific, it seems to be relatively specific for the degradation of acid sphingomyelinase (typically 60-80% of cellular acid sphingomyelinase are degraded), which releases ceramide from sphingomyelin. If the data confirm the beneficial effect of amitriptyline already observed in our preliminary studies, the present clinical study may establish a novel treatment to improve clinical symptoms of cystic fibrosis and, moreover, to prevent or at least delay the onset of cystic fibrosis. Hypothesis - Amitriptyline reduces ceramide concentrations in respiratory epithelial cells (measured in nasal epithelial cells obtained by brushing nasal mucosa). - Amitriptyline treatment reduces cell death in bronchi and deposition of DNA on the respiratory epithelium, which permits elimination of P. aeruginosa from the lung (measured as P. aeruginosa counts in tracheal fluid). - Amitriptyline treatment results in normalization of the function of leukocytes (number determined in serum and tracheal fluid) - Amitriptyline reduces systemic and local inflammation (measured as cytokines in plasma and tracheal fluid). Based on these effects amitriptyline increases the lung function of cystic fibrosis patients (measured by FEV1).
NCT01309178 ↗	Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo	Unknown status	University of Ulm	Phase 2	2009-05-01	Cystic fibrosis patients suffer from a chronic destruction of the lung, frequent and finally chronic pneumonia and a reduced life expectancy. Unfortunately, no curative treatment for cystic fibrosis is available, neither are treatments established that prevent the disease. Our data identify ceramide as a potential novel target to treat cystic fibrosis. Two smaller trials support the notion that inhibition of the acid sphingomyelinase by amitriptyline improves the lung function of CF-patients even at a dose that is low enough to avoid adverse effects. In the present proposal the investigators, therefore, aim to test in a larger cystic fibrosis patient population whether an inhibition of ceramide release in the lung caused by the lack of functional CFTR improves the lung function of cystic fibrosis patients. Inhibition of ceramide-release in the lung will be achieved by treatment with amitriptyline, which is used as an anti-depressant drug for almost 50 years. Although it is not absolutely specific, it seems to be relatively specific for the degradation of acid sphingomyelinase (typically 60-80% of cellular acid sphingomyelinase are degraded), which releases ceramide from sphingomyelin. If the data confirm the beneficial effect of amitriptyline already observed in our preliminary studies, the present clinical study may establish a novel treatment to improve clinical symptoms of cystic fibrosis and, moreover, to prevent or at least delay the onset of cystic fibrosis. Hypothesis - Amitriptyline reduces ceramide concentrations in respiratory epithelial cells (measured in nasal epithelial cells obtained by brushing nasal mucosa). - Amitriptyline treatment reduces cell death in bronchi and deposition of DNA on the respiratory epithelium, which permits elimination of P. aeruginosa from the lung (measured as P. aeruginosa counts in tracheal fluid). - Amitriptyline treatment results in normalization of the function of leukocytes (number determined in serum and tracheal fluid) - Amitriptyline reduces systemic and local inflammation (measured as cytokines in plasma and tracheal fluid). Based on these effects amitriptyline increases the lung function of cystic fibrosis patients (measured by FEV1).
NCT01309178 ↗	Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo	Unknown status	University Children's Hospital Tuebingen	Phase 2	2009-05-01	Cystic fibrosis patients suffer from a chronic destruction of the lung, frequent and finally chronic pneumonia and a reduced life expectancy. Unfortunately, no curative treatment for cystic fibrosis is available, neither are treatments established that prevent the disease. Our data identify ceramide as a potential novel target to treat cystic fibrosis. Two smaller trials support the notion that inhibition of the acid sphingomyelinase by amitriptyline improves the lung function of CF-patients even at a dose that is low enough to avoid adverse effects. In the present proposal the investigators, therefore, aim to test in a larger cystic fibrosis patient population whether an inhibition of ceramide release in the lung caused by the lack of functional CFTR improves the lung function of cystic fibrosis patients. Inhibition of ceramide-release in the lung will be achieved by treatment with amitriptyline, which is used as an anti-depressant drug for almost 50 years. Although it is not absolutely specific, it seems to be relatively specific for the degradation of acid sphingomyelinase (typically 60-80% of cellular acid sphingomyelinase are degraded), which releases ceramide from sphingomyelin. If the data confirm the beneficial effect of amitriptyline already observed in our preliminary studies, the present clinical study may establish a novel treatment to improve clinical symptoms of cystic fibrosis and, moreover, to prevent or at least delay the onset of cystic fibrosis. Hypothesis - Amitriptyline reduces ceramide concentrations in respiratory epithelial cells (measured in nasal epithelial cells obtained by brushing nasal mucosa). - Amitriptyline treatment reduces cell death in bronchi and deposition of DNA on the respiratory epithelium, which permits elimination of P. aeruginosa from the lung (measured as P. aeruginosa counts in tracheal fluid). - Amitriptyline treatment results in normalization of the function of leukocytes (number determined in serum and tracheal fluid) - Amitriptyline reduces systemic and local inflammation (measured as cytokines in plasma and tracheal fluid). Based on these effects amitriptyline increases the lung function of cystic fibrosis patients (measured by FEV1).
NCT01309178 ↗	Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo	Unknown status	University Children’s Hospital Tuebingen	Phase 2	2009-05-01	Cystic fibrosis patients suffer from a chronic destruction of the lung, frequent and finally chronic pneumonia and a reduced life expectancy. Unfortunately, no curative treatment for cystic fibrosis is available, neither are treatments established that prevent the disease. Our data identify ceramide as a potential novel target to treat cystic fibrosis. Two smaller trials support the notion that inhibition of the acid sphingomyelinase by amitriptyline improves the lung function of CF-patients even at a dose that is low enough to avoid adverse effects. In the present proposal the investigators, therefore, aim to test in a larger cystic fibrosis patient population whether an inhibition of ceramide release in the lung caused by the lack of functional CFTR improves the lung function of cystic fibrosis patients. Inhibition of ceramide-release in the lung will be achieved by treatment with amitriptyline, which is used as an anti-depressant drug for almost 50 years. Although it is not absolutely specific, it seems to be relatively specific for the degradation of acid sphingomyelinase (typically 60-80% of cellular acid sphingomyelinase are degraded), which releases ceramide from sphingomyelin. If the data confirm the beneficial effect of amitriptyline already observed in our preliminary studies, the present clinical study may establish a novel treatment to improve clinical symptoms of cystic fibrosis and, moreover, to prevent or at least delay the onset of cystic fibrosis. Hypothesis - Amitriptyline reduces ceramide concentrations in respiratory epithelial cells (measured in nasal epithelial cells obtained by brushing nasal mucosa). - Amitriptyline treatment reduces cell death in bronchi and deposition of DNA on the respiratory epithelium, which permits elimination of P. aeruginosa from the lung (measured as P. aeruginosa counts in tracheal fluid). - Amitriptyline treatment results in normalization of the function of leukocytes (number determined in serum and tracheal fluid) - Amitriptyline reduces systemic and local inflammation (measured as cytokines in plasma and tracheal fluid). Based on these effects amitriptyline increases the lung function of cystic fibrosis patients (measured by FEV1).

Clinical Trial Conditions for CHLORPROTHIXENE

Condition Name

Condition Name for CHLORPROTHIXENE
Intervention	Trials
Schizophrenia	2
Schizoaffective Disorder	1
Anxiety Disorders	1
Bipolar Disorder	1

Condition MeSH

Condition MeSH for CHLORPROTHIXENE
Intervention	Trials
Schizophrenia	2
Disease	2
Bipolar Disorder	1
Pneumonia	1

Clinical Trial Locations for CHLORPROTHIXENE

Trials by Country

Trials by Country for CHLORPROTHIXENE
Location	Trials
Germany	2
Canada	1

Clinical Trial Progress for CHLORPROTHIXENE

Clinical Trial Phase

Clinical Trial Phase for CHLORPROTHIXENE
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for CHLORPROTHIXENE
Clinical Trial Phase	Trials
Completed	1
Terminated	1
Unknown status	1

Clinical Trial Sponsors for CHLORPROTHIXENE

Sponsor Name

Sponsor Name for CHLORPROTHIXENE
Sponsor	Trials
Canadian Network for Observational Drug Effect Studies, CNODES	1
Universität Duisburg-Essen	1
University of Ulm	1

Sponsor Type

Sponsor Type for CHLORPROTHIXENE
Sponsor	Trials
Other	8

Chlorprothixene clinical trials update, market analysis, and patent-and-competition projections (2026)

Last updated: August 1, 2026

Chlorprothixene is an older, first-generation antipsychotic (typical antipsychotic/phenothiazine-class comparator category is often used in databases, though chlorprothixene itself is a thioxanthene derivative). It is used for schizophrenia and other psychoses in some markets, with additional use in agitation/anxiety in practice depending on local approvals. Public clinical-trial activity and current global commercial data for chlorprothixene are thin compared with late-stage “modern antipsychotic” peers, so this outlook is built around: (1) the presence or absence of registered interventional trials in ClinicalTrials.gov and other registries, (2) expected generic and label erosion dynamics typical for older small molecules, and (3) regulatory and IP risk that limits new-company monetization absent new formulations or indications.

What is chlorprothixene’s current clinical trials landscape (ClinicalTrials.gov and registries)?

Answer: Registered interventional trials for chlorprothixene are limited and sporadic versus newer antipsychotics. Where new work occurs, it typically targets formulation, dosing convenience, or comparative efficacy/safety rather than novel mechanisms.

Clinical trial activity patterns for older antipsychotics

• Low probability of brand-sponsored Phase 2/3 because the molecule is off-patent in most jurisdictions and priced as a generic in most established markets.
• Higher likelihood of investigator-initiated studies (safety, tolerability, real-world outcomes) that do not translate into major payer or tender shifts unless bundled into a guideline or regional formularies.
• Formulation or bioavailability studies can show up without changing clinical positioning, but they rarely reaccelerate category-level demand.

Which trial types are most likely for chlorprothixene

• PK/BE or formulation optimization (oral drops, tablets with modified release, combination products)
• Comparative observational studies versus other typical antipsychotics for refractory patients
• Switching studies in institutional settings

What to monitor in trial registry updates

• Posting of Phase 1 PK/BE protocols tied to new dosage forms
• Reclassification of status (Not yet recruiting → Recruiting; Recruiting → Active, not recruiting)
• Recruitment completion dates and results posting (Primary completion date is often stale for older projects)

What does chlorprothixene’s market look like today: demand drivers, channels, and pricing?

Answer: Demand is mainly driven by established psychiatric care pathways in regions where it remains in formularies, with pricing anchored to generic competition. Growth is typically volume-led (continued use in chronic care) rather than premium-led.

Key market drivers

• Treatment of schizophrenia/psychosis in settings that still list typical antipsychotics
• Institutional prescribing where clinicians have long experience with older agents
• Continuity-of-therapy effects: stable patients are less likely to be switched to newer agents if the older drug is tolerated and available

Key constraints

• Motor side effects and sedation associated with first-generation antipsychotics can push formularies toward alternatives (where tolerated)
• Regulatory and label constraints differ by country; availability of chlorprothixene formulations varies by market
• Therapy switching toward second-generation antipsychotics where reimbursement favors them

How does chlorprothixene compare with other antipsychotics in competitive positioning?

Answer: Competitive pressure is mostly from older typicals with similar efficacy and from second-generation antipsychotics with better tolerability profiles, depending on local prescribing culture and formulary incentives.

Competitive comparison (practical)

• Versus second-generation antipsychotics: chlorprothixene typically underperforms on tolerability metrics that influence payer policy, unless there is a strong cost advantage or clinical inertia.
• Versus other typical antipsychotics (phenothiazines, thioxanthenes, butyrophenones): chlorprothixene’s differentiation is usually convenience, clinician familiarity, and local supply.

What generic entry risks exist for chlorprothixene (ANDA/505(b)(2), Para IV, market exclusivity)?

Answer: For an older small molecule, the baseline expectation is generic availability with limited remaining statutory exclusivity, so “Paragraph IV risk” is usually less relevant than “new generic manufacturer” risk and product quality/supply risk.

How exclusivity risk typically plays out for chlorprothixene

• Switch-to-generic behavior once patents lapse and regulatory data exclusivity expires.
• No large brand-style pipeline leverage unless there is a new indication or a novel formulation with its own IP.

What “competitive launches” usually look like

• Multiple ANDA entrants targeting the same listed strengths and dosage forms.
• Price compression in regions where tendering and national procurement apply.

What is the patent estate strength for chlorprothixene, and when does exclusivity end?

Answer: Chlorprothixene is an established older molecule; patent estates for the core compound are generally expired across major markets. Newer IP, if any, would more likely relate to:

• specific formulations (solid oral dose characteristics, salts, particle engineering)
• methods of use (narrow clinical contexts)
• manufacturing processes

IP-driven monetization realities

• Without active formulation or use patents in a specific jurisdiction, monetization is largely residual through generics.
• Any remaining monetization potential usually ties to a surviving secondary patent family that is country- and dosage-form-specific.

What new study outcomes could change chlorprothixene market share?

Answer: Market share typically changes only if new data:

• triggers guideline shifts toward chlorprothixene (rare),
• improves tolerability through a new formulation or dosing approach,
• enables reimbursement expansion (coverage for additional patient subgroups).

High-impact outcome types

• Comparable adverse-event profiles to alternatives in a defined population
• Reduced sedation or extrapyramidal symptom rates via formulation/dosing adjustments
• Demonstrated adherence or switching advantages in real-world registries

Clinical trials update: what is the likely near-term R&D path?

Answer: The near-term pattern for chlorprothixene is more consistent with:

• incremental formulation work than brand-style Phase 3 programs,
• registries and observational studies rather than large randomized outcomes,
• regional trials that meet local regulatory evidence requirements.

12 to 36-month R&D scenarios (base case)

• No material late-stage randomized development that forces guideline reclassification
• More “soft” evidence updates supporting continued use where already established
• A slow drift in share driven by payer policy and tolerability preference across antipsychotic classes

Market projection for chlorprothixene: 2026 to 2031

Answer: Global growth is likely modest and volume-led. The most plausible path is flat-to-low single-digit expansion in markets where chlorprothixene remains a formulary option, with share erosion in regions that shift toward second-generation antipsychotics.

Projection framework (what drives the numbers)

• Number of stocked products (supply continuity)
• Generic price trajectory (tender and procurement cycles)
• Psychiatry prescribing patterns (typical vs second-generation preference)
• Regulatory actions (label restrictions, manufacturing compliance, shortages)

Base case projection

• Worldwide volume: flat to low growth (continuation demand in chronic care)
• Worldwide revenue: flat to declining in many markets due to price compression
• Net effect: modest global revenue resilience, not a growth story

Bull case projection (where upside can come from)

• A surviving secondary IP or new formulation that reduces tolerability burdens enough to maintain inclusion
• Local reimbursement changes that keep chlorprothixene competitive against alternatives
• Supply stabilization that prevents tender-based exclusion

Bear case projection

• Further formulary restrictions as second-generation options remain preferred
• Rising compliance/manufacturing costs for small generic lines
• Persistent tolerability perception limits uptake in new patient starts

Where does chlorprothixene compete geographically (and what that implies for revenue)?

Answer: Revenue persistence is typically stronger in countries with longstanding generic antipsychotic procurement and lower willingness-to-pay for newer agents, and weaker where guidelines and payers push second-generation antipsychotics.

Geographic dynamics

• Europe: mixed, tends to track formulary and guideline choices plus availability of generics
• UK and Nordics: stronger barrier from prescribing preference for second-generation agents (unless local evidence supports typicals)
• Developed markets with structured formularies: share depends on committee decisions and local clinical practice
• Emerging markets: volume can persist due to lower costs and availability, but data transparency and tender volatility are high

What litigation or settlements affect chlorprothixene commercialization?

Answer: For an older molecule without a dominant brand in recent years, there is typically no ongoing multi-defendant patent litigation shaping generics entry. The more relevant commercial risks are regulatory and supply related (manufacturing compliance, inspection outcomes), not Paragraph IV-driven litigation.

Key Takeaways

• Chlorprothixene’s clinical pipeline is likely limited to incremental studies and regionally relevant evidence updates rather than major new Phase 2/3 programs.
• Market trajectory is expected to be constrained by generic competition and tolerability-driven prescribing migration toward second-generation antipsychotics.
• Near-term growth is more plausible as volume retention than revenue expansion; price compression is the dominant revenue risk.
• Material market-share reversals would require new formulation or dosing evidence that measurably improves tolerability and unlocks reimbursement or guideline inclusion.

FAQs

1. Are there any Phase 2/3 randomized trials of chlorprothixene currently recruiting or in progress?
2. Does chlorprothixene have active formulation patents that could delay generic competition in specific countries?
3. Which adverse events most limit chlorprothixene uptake versus second-generation antipsychotics in guideline-driven markets?
4. What do generic pricing and tender cycles typically do to chlorprothixene revenue in Europe?
5. How do label differences across jurisdictions affect chlorprothixene use for schizophrenia and agitation?

References (APA)

1. ClinicalTrials.gov. (n.d.). Chlorprothixene studies. https://clinicaltrials.gov/